Mitotic activity of cultured human lymphocytes treated with gold nanoparticles
Iraqi Journal of Cancer and Medical Genetics · 2018
DOI: 10.29409/ijcmg.v10i2.219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iraqi Journal of Cancer and Medical Genetics, 2018. Verfasst von Sumaiah I. Hussein.
Abstract (Originalsprache)
Potential health and environmental effects of nanoparticles need to be thoroughly assessed before their widespread commercialization.The present investigation was planned with the aims to determine the effects of gold nanoparticles (GNPs) onblast (BI) and mitotic (MI) indices of cultured lymphocytes. The results revealed that BI (50.3 ± 2.3, 30.2 ± 1.9, 10.5 ± 0.7 and0.0%, respectively) and MI (70.1 ± 2.9, 20.4 ± 1.1, 5.3 ± 0.1 and 0.0%, respectively) showed a gradual decreased percentageas the concentration of GNPs was increased from 0.085 to 0.66 μg/mL, and the difference was significant compared to controlculture (81.6 ± 2.5 and 90.2 ± 3.7%, respectively). A maximum inhibition of BI and MI was occurred at the concentration 0.66μg/mL. In conclusion, GNPs can be considered as a growth inhibiting agent, but it is too early to reach a final conclusion inthis regard and further investigations are required to elucidate the biochemical mechanisms involved in inhibiting the mitoticactivity of lymphocytes.Key word: gold nanoparticles, mitotic index, blast index, lymphocytes
Zitieren
APA
Hussein, S. I. (2018). Mitotic activity of cultured human lymphocytes treated with gold nanoparticles. Iraqi Journal of Cancer and Medical Genetics. https://doi.org/10.29409/ijcmg.v10i2.219
Vancouver
Hussein SI. Mitotic activity of cultured human lymphocytes treated with gold nanoparticles. Iraqi Journal of Cancer and Medical Genetics. 2018. doi:10.29409/ijcmg.v10i2.219
BibTeX
@article{Hussein2018,
author = {Hussein, Sumaiah I.},
title = {Mitotic activity of cultured human lymphocytes treated with gold nanoparticles},
journal = {Iraqi Journal of Cancer and Medical Genetics},
year = {2018},
doi = {10.29409/ijcmg.v10i2.219}
}
EUVIMED